ASH 2022 | MRD as a prognostic tool but not for clinical decision-making in multiple myeloma
Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses the use of measurable residual disease (MRD) negativity as a prognostic factor in multiple myeloma, citing the results of the MASTER trial (NCT03224507) as evidence that patients with MRD negativity paired with a stringent complete response (CR) may not require indefinite maintenance therapy. However, Dr Gertz currently cautions against using MRD as a driver for clinical decision-making outside of trial settings. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Ionis/Akcea: Other: personal fees; Prothena: Other: personal fees; Sanofi: Other: personal fees; Janssen: Other: personal fees; Aptitude Healthgrants: Other: personal fees; Ashfield: Other: personal fees; Juno: Other: personal fees; Physicians Education Resource: Other: personal fees; Abbvie: Membership on an entity’s Board of Directors or advisory committees, Other: personal fees from Data Safety Monitoring Board; Johnson & Johnson: Other: personal fees; Celgene: Other: personal fees; Research to Practice: Other: personal fees; Sorrento: Other: personal fees; i3Health: Other: Development of educational materials for i3Health.
